Based on our results from Adcy3∆AT mice, pharmacologically inactivating Adcy3-at expression or impeding the interaction of AC3-AT with AC3 could pave the way to reactivate BAT function and mitigate obesity and obesity-related metabolic decline. The gene discussed is ADCY3; the disease is obesity due to melanocortin 4 receptor deficiency.